The drug, typically taken once a week, would cost between Rs 14,000 and Rs 17,500 per month, depending on the dosage ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India-here's what ...

GPs are free to prescribe semaglutide to all eligible patients in line with NICE guidelines after long-term shortages have ...

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

Of the 37.1 million patients with type 2 diabetes, 810,390 were new semaglutide users, 326,282 were treated with dulaglutide, 25,936 with exenatide (Byetta, Bydureon), 715,802 with empagliflozin ...

showing that once-weekly semaglutide significantly reduced HbA1c and body weight in persons with type 2 diabetes when compared to dulaglutide. Additionally, the obesity segment is predicted to ...

Adults with type 2 diabetes using semaglutide, dulaglutide (Trulicity, Eli Lilly), exenatide, empagliflozin (Jardiance, Boehringer Ingelheim), sitagliptin (Januvia, Merck) or glipizide from ...

The phase 3 trial success over Lilly’s Trulicity (dulaglutide), an already-marketed GLP-1 class rival, further bolsters semaglutide's profile ahead of its anticipated approval later this year as ...